Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
US authorities looking into price fixing in the generics industry are now investigating 16 companies and the price of at least 300 drugs, according to a press report.
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m
Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.
NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug.